<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00716690</url>
  </required_header>
  <id_info>
    <org_study_id>MYS-04-HMO-CTIL</org_study_id>
    <nct_id>NCT00716690</nct_id>
  </id_info>
  <brief_title>Multi Donor Mismatched Stem Cell Transplantation (MDT)</brief_title>
  <official_title>Enhancement of Hematopoietic Stem Cell Engraftment by Multi Donor Stem Cell Transplantation (MDT) From 2 Mismatched Donors, a Phase I-II Open Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed research focuses on the development of innovative protocol of mismatched stem
      cell transplantation with combined 2 different haplo stem cell transplantation (SCT) donors
      which are mismatched to the recipient (and preferably to each other), in a patient in need
      for SCT, lacking an HLA match related or an unrelated donor. This innovative protocol named
      multi donor stem cell transplantation (MDT) is designed to facilitate engraftment even when
      reduced intensity conditioning or a low cell dose are used, improve the graft vs. leukemia
      (GVL) effect and enhance immune reconstitution (using quantitative and qualitative
      parameters).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Day of neutrophil engraftment</measure>
    <time_frame>30d</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Day of platelet engraftment&gt;20x10(9)L</measure>
    <time_frame>30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute GVHD occurrence&gt;2</measure>
    <time_frame>100d</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>100d</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Day of platelet engraftment&gt;50x10(9)/L</measure>
    <time_frame>30d</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of acute GVHD</measure>
    <time_frame>100d</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVHD grade</measure>
    <time_frame>100d</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections incidence</measure>
    <time_frame>100d</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transplant-related mortality</measure>
    <time_frame>100d</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant related toxicity</measure>
    <time_frame>100d</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution</measure>
    <time_frame>100d</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Graft-Versus-Host Disease</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Multi donor stem cell transplantation</intervention_name>
    <description>stem cell transplantation from 2 donors</description>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patient age 0-70 years old with leukemia in 1st remission at high risk of relapse
             because of unfavorable prognostic features, at 2nd CR or MDS without an readily
             available matched donor (related or unrelated).

          2. Patients must have a mismatched donor willing and capable of donating peripheral blood
             stem cells and/or bone marrow progenitor cells using conventional techniques, and
             lymphocytes if indicated (mismatched defined as 3/6-4/6 HLA matching).

          3. Each patient / patient's guardian must sign written informed consent.

          4. Patients must have an ECOG PS â‰¤ 2; Creatinine &lt;2.0 mg/dl; Ejection fraction &gt;40%; DLCO
             &gt;50% of predicted; Serum bilirubin &lt;3 gm/dl; elevated GPT or GOT &lt;3 x normal values.

        Exclusion criteria:

          1. Not fulfilling any of the inclusion criteria.

          2. Not in CR (if the indication for transplant is leukemia).

          3. Active life-threatening infection.

          4. Overt untreated infection.

          5. HIV seropositivity, Hepatitis B or C antigen positivity with evidence of active
             hepatitis.

          6. Pregnant or lactating women.

          7. Donor contraindication (HIV seropositive confirmed by Western Blot, Hepatitis B
             antigenemia, HCV, evidence of bone marrow disease, unable to donate bone marrow or
             peripheral blood due to concurrent medical condition).

          8. Previous autologous or allogeneic stem cell transplantation.

          9. Inability to comply with study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Y Shapira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Y Shapira, MD</last_name>
    <phone>00 972 2 6778351</phone>
    <email>shapiram@hadassah.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arik Tzukert, DMD</last_name>
      <phone>00 972 2 6776095</phone>
      <email>arik@hadassah.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Hadas Lemberg, PhD</last_name>
      <phone>00 972 2 6777572</phone>
      <email>lhadas@hadassah.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Shapira Y Michael, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2008</study_first_submitted>
  <study_first_submitted_qc>July 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2008</study_first_posted>
  <last_update_submitted>February 18, 2016</last_update_submitted>
  <last_update_submitted_qc>February 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hadassah Medical Organization</investigator_affiliation>
    <investigator_full_name>SHAPIRA MICHAEL</investigator_full_name>
    <investigator_title>Prof Shapira</investigator_title>
  </responsible_party>
  <keyword>Stem cell transplantation</keyword>
  <keyword>GVHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

